Stainless Steel vs Single-Use Chromatography Systems for Biopharmaceutical Protein Purification

Where Stainless Steel Chromatography Still Wins

Stainless steel chromatography is the use of hard-piped, fixed flow paths and reusable columns built from 316L electropolished stainless steel for biopharmaceutical protein purification. It is the dominant format for commercial monoclonal antibody manufacturing, and despite the rapid rise of single-use systems below 2,000 L upstream scale, stainless steel chromatography retains four structural advantages that keep it embedded in large-scale downstream processing.

First, the resin inside a stainless steel column can be cycled 100-500 times depending on chemistry, which spreads the dominant cost of Protein A resin across thousands of grams of product. Second, the column housing tolerates working pressures of 3-5 bar and supports bed volumes from 50 L to over 1,000 L, where single-use prepacked formats are capped at roughly 2-4 bar and 60 L. Third, stainless steel is chemically inert to the harsh sodium hydroxide CIP cycles that drive resin lifetime extension. Fourth, the cleaning-validated, hard-piped flow path delivers the lowest extractables and leachables risk at commercial scale — an established regulatory pathway with decades of approved precedent.

These advantages compound in the specific economic regime where stainless steel chromatography dominates: high annual product mass, long product life cycles, and high column-loading utilisation. Below that regime, single-use chromatography wins on changeover speed, capital expenditure, and multi-product flexibility. The remainder of this article quantifies the crossover point and lays out how to choose between the two formats for a real protein purification process.

The Economics: Cost-per-Gram vs Annual Volume

The economic crossover between stainless steel and single-use chromatography is driven by one number: the cost of resin per gram of purified product. At commercial volumes, the resin is the dominant cost line in capture chromatography, and the stainless steel format spreads it across far more cycles than single-use can match.

Consider Protein A capture, the canonical chromatography step for monoclonal antibody manufacturing. A modern alkali-stable Protein A resin (Cytiva MabSelect PrismA, Purolite Praesto AP, Tosoh TOYOPEARL AF-rProtein A) costs in the range of $10,000-15,000 per litre of packed resin at commercial volume. Dynamic binding capacity at 6 minute residence time is typically 70-80 g/L. The resin's cycle life under optimised 0.1 M NaOH cleaning is reproducibly 150-200 cycles before dynamic binding capacity drops below the 80% retention threshold.

In a hard-piped stainless steel column, that resin batch processes (150 cycles × 70 g/L × column volume) of product before replacement. For a 200 L bed volume column, that is 2.1 tonnes of mAb captured by a single $2-3 million resin charge. In a single-use prepacked column at clinical scale, the same resin is typically cycled 10-50 times before the column is discarded as part of a planned single-use strategy — capturing only 140 to 700 kg before the consumable cost recurs.

The crossover scale depends on cycle strategy, but published modelling consistently puts it near 100-500 kg of annual product mass for a single product running multiple years. Below that scale, the CapEx and changeover savings of single-use dominate. Above it, the resin economics of stainless steel chromatography pull ahead.

Two facility-level cost drivers are easy to miss but matter at scale. Stainless steel chromatography carries a one-off cleaning validation burden of roughly $100,000-500,000 plus ongoing requalification, and supports a fully closed flow path only when paired with steam-in-place capability. Single-use chromatography eliminates the cleaning validation entirely, accelerates changeover by 30-60% in multi-product facilities, and ships pre-qualified at the column level — but adds a recurring consumable line that grows linearly with batches.

Scale, Pressure, and Bed Volume

Stainless steel chromatography supports bed volumes and pressures that single-use formats cannot physically match. Process-scale 316L columns are routinely packed at 200-600 L bed volume in commercial mAb plants, with custom builds at 1-2 m internal diameter reaching 1,000 L. The largest single-use prepacked columns commercially available as of 2026 are approximately 60 L bed volume (Repligen OPUS 80 cm, Cytiva ReadyToProcess 45 cm).

This 10-fold gap is the single biggest reason commercial mAb facilities producing more than 500 kg/year stay on stainless steel for capture. A 500 kg/year process at 5 g/L titre and 30 g/L loading capacity needs roughly 3.3 tonnes of harvest fluid processed per batch — comfortable for a 200 L stainless steel column on a 4-cycle batch, impractical to schedule across a stack of 60 L single-use columns.

The pressure ceiling is the second physical constraint. Stainless steel columns are rated to 3-5 bar working pressure as a process standard, and certain axial-compression designs (e.g., Cytiva BPG, Repligen ProConnex) accept 6-10 bar. Single-use prepacked columns are limited by the polymeric housing material to roughly 2-4 bar. Higher operating pressure permits faster linear flow rates and the use of smaller bead diameter resins (45 µm versus 65-90 µm), which give sharper peaks, higher resolution, and tighter binding kinetics — advantages most relevant in polishing and high-resolution ion-exchange separations.

The chemical resistance of 316L stainless steel matters more than it looks. Protein A resin lifetime extension depends on rigorous cleaning-in-place with 0.1-0.5 M sodium hydroxide, sometimes combined with sodium chloride or guanidine for hard-to-remove host cell protein deposits. 316L tolerates these conditions indefinitely; the polymeric housings of single-use columns degrade faster, which sets a practical ceiling on the number of CIP cycles a single-use column will accept before structural failure or leachable migration.

Resin Reuse and Protein A Lifecycle Economics

The cycle life of Protein A resin is the single largest economic lever in monoclonal antibody downstream processing, and stainless steel chromatography exists in part to make that lever work. Each additional cycle directly reduces the resin cost per gram of product. Doubling cycle life from 100 to 200 cycles halves the resin cost contribution, and modelling published by Klutz et al. (2016) shows that resin cost is the largest single contributor to the all-in cost of capture chromatography at commercial scale.

Documented Protein A cycle lifetimes from peer-reviewed and vendor-published data span:

• Legacy native Protein A (rProtein A Sepharose Fast Flow, ProSep Ultra Plus): 50-100 cycles, limited by alkaline degradation of the native A protein
• First-generation alkali-stable (MabSelect SuRe): 100-150 cycles under 0.1 M NaOH cleaning
• Modern alkali-stable (MabSelect PrismA, Praesto AP, Amsphere A3): 150-200 cycles documented, with some vendor protocols extending to 300 cycles for fully optimised cleaning regimes

Realising the upper end of these ranges requires consistent CIP protocol, controlled column inlet conditions, and ongoing dynamic binding capacity tracking — all easier to deliver in a hard-piped stainless steel skid with embedded sensors and validated cleaning. The single-use equivalent typically commits to a shorter cycle target (often 10-50 cycles) to avoid the regulatory effort of validating extended reuse on a polymeric housing.

Two operational practices help stainless steel reach the high end of cycle life. First, in-line dynamic binding capacity monitoring — using either UV breakthrough at a known load percentage or trend analysis of elution peak area — allows replacement to be triggered on actual performance rather than a conservative cycle count. Second, harvest clarification quality drives column fouling; tighter depth filtration sizing upstream of the column extends cycle life by reducing particulate load on the resin bed.

Single-Use Chromatography Advantages

Single-use chromatography wins on speed, flexibility, and CapEx, and these advantages are real at clinical and early commercial scale. No analysis of stainless steel versus single-use chromatography is honest without explicit recognition of where single-use systems pull ahead.

The primary advantage is changeover time. Switching products on a stainless steel skid requires a full cleaning validation cycle, equipment qualification, and often a documented hold-test — routinely 1-3 days of facility downtime per product change. Single-use chromatography eliminates the cleaning step entirely: the prepacked column and flow path are discarded, and the skid hardware (often itself wetted only by single-use manifolds) is ready for the next product in 2-6 hours. For a contract manufacturer running 8-12 different products per year, this changeover saving can recover the entire consumable premium.

The second advantage is cleaning validation. Hard-piped stainless steel chromatography requires demonstrating sub-acceptance-limit carryover of both product and cleaning agents on every wetted surface, a one-off effort of $100,000-500,000 and ongoing requalification on every cleaning cycle change. Single-use removes this burden: the wetted path is single-cycle by definition, and the extractables and leachables risk is addressed through USP <665> qualification of the consumable rather than per-facility cleaning studies.

The third advantage is CapEx and footprint. A complete single-use chromatography skid (Cytiva ÄKTA Ready, Sartorius Cadence BioSMB, Pall Allegro) costs $300,000-600,000 at commercial scale, against $0.8-2.5 M for an equivalent hard-piped stainless steel system. The hard-piped system also needs dedicated room infrastructure: drains, CIP supply lines, SIP capability, and floor loading for the heavier vessels.

The fourth advantage is multi-product flexibility. Cell and gene therapy facilities, biosimilar contract manufacturers, and early clinical pipelines all benefit from a single suite that can run 6-15 different products per year. Single-use chromatography is the only practical format for these contexts because cleaning validation across that many products on shared stainless steel hardware becomes economically and operationally infeasible.

Decision Framework: When to Choose Each

The choice between stainless steel and single-use chromatography reduces to four questions: annual product mass, product life cycle, multi-product use, and pressure-resolution requirements. The decision tree below captures how the answers compound in practice.

The four override conditions matter more than the headline mass threshold in many practical situations. A 300 kg/year contract manufacturing programme running 6 different products will still pick single-use because cleaning validation costs swamp the resin savings. A 30 kg/year orphan biologic will still pick stainless steel if the polishing step demands a small-bead resin operating at 6 bar. The base recommendation by volume is the starting point, not the final answer.

Hybrid Trains and Future Trends

The most common downstream configuration in 2026 biopharmaceutical manufacturing is a hybrid train, with stainless steel chromatography for the capture step and single-use chromatography for one or both polishing steps. This pattern captures the resin economics of steel where the resin cost is highest (Protein A) and the flexibility of single-use where the resin is cheaper and the operational tempo matters more.

A representative hybrid mAb downstream train looks like:

• Capture: Stainless steel Protein A column (150-300 L bed), 150-200 cycles per resin charge
• Viral inactivation: Single-use mixing tank with low-pH hold
• Polish 1 (intermediate): Single-use prepacked anion exchange (flow-through or bind-elute) column, 10-50 cycles before discard
• Polish 2: Single-use prepacked cation exchange or multimodal column, often 1-10 cycles per product lot
• Viral filtration and UF/DF: Single-use cassettes and capsules

Three trends are likely to reshape this picture over the next 3-5 years. First, larger single-use columns. Vendor roadmaps point to prepacked formats above 100 L bed volume, which would push the stainless steel mass threshold from ~200 kg/year toward 500 kg/year and shrink the SS-only zone. Second, continuous chromatography — both PCC and CaptureSMB capture formats — reduces the bed volume needed for a given throughput, making smaller single-use columns viable at higher mass scales. Third, hybrid skid platforms like Cytiva's ÄKTA Process with interchangeable flow paths blur the binary choice, letting a single facility configure the same skid as either stainless steel or single-use per product.

The deeper trend, however, is that the question itself is shifting. The relevant comparison is no longer "stainless steel chromatography versus single-use chromatography" but "where in my facility does each format pay back its installed cost." For sustained commercial mAb production, that answer keeps stainless steel embedded in the capture step. For everything else, single-use is winning.

Frequently Asked Questions

When is stainless steel chromatography more cost-effective than single-use?

Stainless steel chromatography becomes more cost-effective when annual production exceeds roughly 100-200 kg of purified protein per product, or when the same product runs for more than 4-5 years. At those volumes the amortised resin cost drops below the per-cycle cost of prepacked single-use columns, because a Protein A column packed in a stainless steel housing can deliver 100-200 cycles of useful life, while a single-use prepacked column is typically discarded after 1-50 cycles depending on the process and regulatory strategy.

What is the typical pressure rating for stainless steel chromatography columns?

Process-scale stainless steel chromatography columns are typically rated to 3-5 bar working pressure, with some compact-style designs (e.g., axial-compression columns) operating up to 6-10 bar. Most single-use prepacked columns are limited to 2-4 bar by the polymeric housing. The higher pressure ceiling of stainless steel allows faster linear flow rates and the use of smaller-bead, higher-resolution resins that would otherwise generate prohibitive back-pressure.

How many cycles can a stainless steel chromatography column be reused?

The stainless steel housing itself is essentially permanent and lasts for the life of the facility with routine inspection. The resin inside has a finite cycle life: modern alkali-resistant Protein A resins (MabSelect PrismA, Praesto AP) are validated for 150-200 cycles under optimised cleaning-in-place protocols, while ion-exchange and mixed-mode resins typically tolerate 200-500 cycles. Cycle life is defined by dynamic binding capacity decay (commonly an 80-90% retention threshold) rather than mechanical failure of the column hardware.

What is the largest single-use chromatography column commercially available?

As of 2026 the largest single-use prepacked chromatography columns are around 60 L bed volume (e.g., Repligen OPUS 80 cm columns, Cytiva ReadyToProcess 45 cm columns). For comparison, hard-piped stainless steel columns used in commercial monoclonal antibody manufacturing routinely operate at 200-600 L bed volume, with 1-2 m diameter custom builds reaching 1,000 L or more. This 10-fold bed-volume gap is the primary reason commercial-scale mAb facilities still default to stainless steel for capture chromatography.

Is single-use chromatography accepted by regulators for commercial GMP manufacturing?

Yes. FDA and EMA have approved commercial biologics manufactured using single-use chromatography flow paths and prepacked columns, particularly for cell and gene therapy products and lower-volume biosimilars. The regulatory expectation is the same as for stainless steel: demonstrated process consistency, validated cleaning (or single-cycle use), and a robust extractables and leachables assessment per USP <665> and BPOG guidance. Single-use is now the default for early clinical manufacturing and is rapidly displacing stainless steel up to roughly 2,000 L scale.

Can you mix stainless steel and single-use chromatography in the same process?

Yes, hybrid trains are now common. A typical pattern uses a stainless steel Protein A capture column (because the resin is the dominant cost and high cycle reuse pays back the housing) followed by single-use prepacked polishing columns (because the polishing resins are cheaper, the load is cleaner, and changeover is faster). The flow path between columns can be single-use manifold tubing or hard-piped depending on multi-product flexibility needs.

Related Tools

• Chromatography Calculator — Size a column for any feed volume, titre, DBC, and residence time, and estimate buffer consumption per cycle.
• Resin Lifetime Calculator — Model cost per gram of product as a function of resin price, cycle life, and DBC decay.
• Viral Clearance LRV Calculator — Cumulative log reduction across capture, polishing, and viral filtration in a complete DSP train.

References

1. Shukla AA, Thommes J. Recent advances in large-scale production of monoclonal antibodies and related proteins. Trends Biotechnol. 2010;28(5):253–261. doi:10.1016/j.tibtech.2010.02.001
2. Klutz S, Holtmann L, Lobedann M, Schembecker G. Cost evaluation of antibody production processes in different operation modes. Chem Eng Sci. 2016;141:63–74. doi:10.1016/j.ces.2015.10.029
3. Pollock J, Coffman J, Ho SV, Farid SS. Integrated continuous bioprocessing: Economic, operational, and environmental feasibility for clinical and commercial antibody manufacture. Biotechnol Prog. 2017;33(4):854–866. doi:10.1002/btpr.2492
4. Shukla AA, Wolfe LS, Mostafa SS, Norman C. Evolving trends in mAb production processes. Bioeng Transl Med. 2017;2(1):58–69. doi:10.1002/btm2.10061
5. Walther J, Godawat R, Hwang C, Abe Y, Sinclair A, Konstantinov K. The business impact of an integrated continuous biomanufacturing platform for recombinant protein production. J Biotechnol. 2015;213:3–12. doi:10.1016/j.jbiotec.2015.05.010

← See all bioprocess comparisons